Can a triple therapy halt smoldering myeloma before it strikes?
NCT ID NCT04933539
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a condition that often leads to active cancer. The goal is to see if this treatment can prevent or delay the disease from becoming symptomatic and causing organ damage. Fourteen participants will receive the drugs for up to 12 cycles, followed by daratumumab alone, and will be monitored for life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daratumumab, carfilzomib, and dexamethasone
What this could lead to
If successful, this could delay or prevent smoldering myeloma from turning into active multiple myeloma, potentially reducing organ damage and extending life without symptoms.
What could go wrong
This is a small, early-phase trial with only 14 participants, so results may not apply broadly. The drugs can cause side effects like heart or lung problems, and the treatment may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.